Dermatol. praxi. 2017;11(4):209-210

Tumor necrosis factor alpha (TNFα) inhibitors in the treatment of severe forms of psoriasis

MUDr. Jan Hugo, MUDr. Spyridon Gkalpakiotis, Ph.D., MBA
Dermatovenerologická klinika 3. LF UK a FNKV, Praha

The article provides a brief overview of the biological therapy of psoriasis, focusing on the most commonly used class of drugs,the TNFα inhibitors.

Keywords: psoriasis, biologic therapy, TNFα inhibitors

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hugo J, Gkalpakiotis S. Tumor necrosis factor alpha (TNFα) inhibitors in the treatment of severe forms of psoriasis. Dermatol. praxi. 2017;11(4):209-210.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gudjonsson JE, Elder JT. Psoriasis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ, Wolff K, editors. Fitzpatrick's dermatology in general medicine. 8th ed. USA: McGraw Hill Companies, Inc; 2012.
    2. Van De Kerkhof P. Psoriasis. In: Bolognia J, Jorizzo JL, Schaffer J, editors. Dermatology. 3rd ed., vol 1. China: Saunders Elsevier; 2012. p. 135-156.
    3. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, van de Kerkhof P, St?hle M, Nestle FO, Girolomoni G, Krueger JG. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010; 130(7): 1785-1796. Go to original source... Go to PubMed...
    4. Prussick R, Unnebrink K, Valdecantos WC. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis. J Drugs Dermatol. 2015; 14(8): 864-868. Go to PubMed...
    5. Kolios AG, Yawalkar N, Anliker M, et al. Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology, 2015; 232: p. 385-406. Go to original source... Go to PubMed...
    6. Menter A, Korman NJ, Elmets CA, et al Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treamtent of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol, 2010; 62: p. 114-135. Go to original source... Go to PubMed...
    7. Mrowietz U, De jong EM, Kragballe K, et al. A consesnus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol. Venereol, 2014; 28: p. 438-453. Go to original source... Go to PubMed...
    8. Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Long version - EDF in cooperation with EADV and IPC. J Eur Acad Dermtol. Venereol, 2015; 29: p. 2277-2294. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.